227 related articles for article (PubMed ID: 10339507)
1. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
[TBL] [Abstract][Full Text] [Related]
2. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
3. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
[TBL] [Abstract][Full Text] [Related]
4. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
Svingen PA; Tefferi A; Kottke TJ; Kaur G; Narayanan VL; Sausville EA; Kaufmann SH
Clin Cancer Res; 2000 Jan; 6(1):237-49. PubMed ID: 10656455
[TBL] [Abstract][Full Text] [Related]
5. Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells.
Carlo-Stella C; Regazzi E; Garau D; Mangoni L; Rizzo MT; Bonati A; Dotti G; Almici C; Rizzoli V
Br J Haematol; 1996 Jun; 93(3):551-7. PubMed ID: 8652372
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
Sun X; Layton JE; Elefanty A; Lieschke GJ
Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
[TBL] [Abstract][Full Text] [Related]
7. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis.
Selleri C; Maciejewski JP; Pane F; Luciano L; Raiola AM; Mostarda I; Salvatore F; Rotoli B
Blood; 1998 Aug; 92(3):981-9. PubMed ID: 9680367
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
9. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors.
Kasper B; Fruehauf S; Schiedlmeier B; Buchdunger E; Ho AD; Zeller WJ
Cancer Chemother Pharmacol; 1999; 44(5):433-8. PubMed ID: 10501919
[TBL] [Abstract][Full Text] [Related]
10. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
[TBL] [Abstract][Full Text] [Related]
11. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Deininger MW; Goldman JM; Lydon N; Melo JV
Blood; 1997 Nov; 90(9):3691-8. PubMed ID: 9345054
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia.
Selleri C; Sato T; Del Vecchio L; Luciano L; Barrett AJ; Rotoli B; Young NS; Maciejewski JP
Blood; 1997 Feb; 89(3):957-64. PubMed ID: 9028327
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
Urbano A; Gorgun G; Foss F
Biochem Pharmacol; 2002 Feb; 63(4):689-92. PubMed ID: 11992636
[TBL] [Abstract][Full Text] [Related]
15. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
[TBL] [Abstract][Full Text] [Related]
16. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
[TBL] [Abstract][Full Text] [Related]
17. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
[TBL] [Abstract][Full Text] [Related]
18. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
19. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Hiwase DK; White DL; Powell JA; Saunders VA; Zrim SA; Frede AK; Guthridge MA; Lopez AF; D'Andrea RJ; To LB; Melo JV; Kumar S; Hughes TP
Leukemia; 2010 Apr; 24(4):771-8. PubMed ID: 20130598
[TBL] [Abstract][Full Text] [Related]
20. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Wisniewski D; Lambek CL; Liu C; Strife A; Veach DR; Nagar B; Young MA; Schindler T; Bornmann WG; Bertino JR; Kuriyan J; Clarkson B
Cancer Res; 2002 Aug; 62(15):4244-55. PubMed ID: 12154026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]